| Name | Title | Contact Details |
|---|
RubrYc Therapeutics is a biotechnology company that integrates chemistry and computation to decode therapeutically significant protein interfaces, revolutionizing the discovery of antibody-based drugs.
Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops, and intends to commercialize innovative therapies that use a novel approach to target G protein coupled receptors, or GPCRs. We are dedicated to providing value to patients and healthcare providers by improving patient outcomes and reducing healthcare costs. We have identified four biased ligand drug candidates: TRV130, an FDA-designated Breakthrough Therapy, is currently in phase 3 testing for the intravenous treatment of acute moderate to severe pain; TRV027 was evaluated in a Phase 2b study for the treatment of acute heart failure; TRV734 has completed phase 1 testing for oral treatment of acute and chronic pain; and TRV250 is in preclinical development for the treatment of migraine. In addition, Trevena has an early stage portfolio of drug discovery programs currently in lead optimization.
Epirium Bio is a clinical-stage biopharmaceutical company developing therapeutics that promote mitochondrial biogenesis and function through a novel mechanism of action discovered by the company.
Two Pore Guys has created a digital, hand-held, single molecule biosensor that rivals the sensitivity of expensive medical lab equipment, yet is as inexpensive and easy to use as a blood glucose monitor.
Incept BioSystems is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.